New drug combo may let some esophageal cancer patients skip surgery
NCT ID NCT07584031
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study tests a drug called adebrelimab combined with chemotherapy before either watchful waiting or surgery for people with a type of esophageal cancer. About 200 participants will receive the treatment first. If their cancer disappears completely, they will be randomly assigned to either watchful waiting with more chemo-immunotherapy or standard surgery. The goal is to see if watchful waiting can work as well as surgery, improving survival and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.